Department of Nephrology, Klinikum rechts der Isar, Technische Universitaet Muenchen, Germany.
Autoimmun Rev. 2010 Jun;9(8):540-6. doi: 10.1016/j.autrev.2010.02.016. Epub 2010 Mar 6.
Relapsing polychondritis (RPC) is a rare immune mediated disease which is associated with inflammation in cartilaginous tissue throughout the body. Especially the cartilaginous structures of ear, nose, joints and respiratory tract are affected. In around 30% of the cases an association with other diseases especially systemic vasculitis or myelodysplatic syndrome can be detected. The relative rarity of RPC has not permitted clinical trials to determine the efficacy and safety of therapy strategies. Often the medication in current use is largely empiric and based on case reports. Therefore different immunosuppressants such as cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil and also new approaches like tumor necrosis factor alpha blockers (TNF-alpha antagonists) have been used for the treatment of severe manifestations of RPC with varying degrees of efficacy. This review gives a close look to clinical manifestation, diagnosis and also therapy options of RPC.
复发性多软骨炎(RPC)是一种罕见的免疫介导性疾病,与全身软骨组织炎症有关。特别是耳部、鼻部、关节和呼吸道的软骨结构受到影响。大约 30%的病例可检测到与其他疾病的关联,特别是系统性血管炎或骨髓增生异常综合征。RPC 的相对罕见性使得临床试验无法确定治疗策略的疗效和安全性。目前常用的药物在很大程度上是经验性的,并且基于病例报告。因此,已经使用了不同的免疫抑制剂,如环磷酰胺、硫唑嘌呤、环孢素、霉酚酸酯和新型方法,如肿瘤坏死因子-α 阻滞剂(TNF-α 拮抗剂),用于治疗 RPC 的严重表现,疗效不一。这篇综述详细介绍了 RPC 的临床表现、诊断和治疗选择。